Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer

ClinicalTrials.gov ID: NCT01269346

Public ClinicalTrials.gov record NCT01269346. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 4:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Positive Breast Cancer

Study identification

NCT ID
NCT01269346
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Eisai Inc.
Industry
Enrollment
52 participants

Conditions and interventions

Conditions

Interventions

  • Eribulin Mesylate Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2010
Primary completion
Feb 28, 2013
Completion
Apr 30, 2016
Last update posted
Jun 21, 2023

2010 – 2016

United States locations

U.S. sites
26
U.S. states
15
U.S. cities
25
Facility City State ZIP Site status
University of Colorado Denver Colorado 80204
Florida Cancer Care Davie Florida 33328
Florida Oncology Associates Jacksonville Florida 32256
Ocala Oncology Center Ocala Florida 34471
Peachtree Hematology Oncology Associates, PC Atlanta Georgia 30309
Northwest Georgia Oncology Centers, P.C. Marietta Georgia 30060
Montgomery Cancer Center Mount Sterling Kentucky 40353
Jackson Oncology Associates, PLLC Jackson Mississippi 39202
Heartland Regional Medical Center Saint Joseph Missouri 64507
Weill Cornell Breast Clinic New York New York 10065
Raleigh Hematology Associates Raleigh North Carolina 27607
Cancer Care of the Cascades Bend Oregon 97701
Medical Oncology Associates of Wyoming Valley, P.C. Kingston Pennsylvania 18704
Charleston Hematology/Oncology Charleston South Carolina 29403
Medical University of South Carolina Charleston South Carolina 29403
C. Michael Jones, MD Germantown Tennessee 38138
Texas Oncology - Beaumont Marnie McFaddin Ward Cancer Center Beaumont Texas 77702-1449
Texas Oncology - Medical City Dallas Dallas Texas 75201
Texas Oncology - El Paso Cancer Treatment Center Grandview El Paso Texas 79902
Texas Oncology - Memorial City Houston Texas 77024
Texas Oncology - McAllen South Second Street McAllen Texas 78503
Cancer Care Centers of South Texas San Antonio Texas 78217
Texas Oncology - Sherman Sherman Texas 75090
Texas Oncology - Sugar Land Sugar Land Texas 77479
Pensisula Cancer Institute Newport News Virginia 23601
Columbia Basin Hematology and Oncology Kennewick Washington 99336

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01269346, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 21, 2023 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01269346 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →